NCT02282345View on ClinicalTrials.gov

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 16, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

June 7, 2022

Conditions
Breast AdenocarcinomaDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationHER2/Neu NegativeInvasive Breast Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Talazoparib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02282345 - Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | Biotech Hunter | Biotech Hunter